Response to Treatment by Ara-C Induction Dose and Expression of Multidrug Resistance Protein MDR1 Among 352 AML Patients
| . | Patients Randomized to SDAC . | Patients Randomized to HDAC . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients . | % CR . | 95% CI (%) . | % RD . | 95% CI (%) . | No. of Patients . | % CR . | 95% CI (%) . | % RD . | 95% CI (%) . | |
| MDR1 (MRK16) | ||||||||||
| Bright | 43 | 49 | 34-64 | 35 | 21-49 | 21 | 48 | 26-69 | 38 | 17-59 |
| Moderate | 26 | 46 | 27-65 | 42 | 23-61 | 9 | 44 | 14-79 | 22 | 3-60 |
| Dim | 16 | 69 | 41-85 | 25 | 7-52 | 8 | 50 | 16-84 | 25 | 3-65 |
| Negative | 160 | 52 | 44-60 | 25 | 18-32 | 68 | 59 | 47-71 | 19 | 10-28 |
| . | Patients Randomized to SDAC . | Patients Randomized to HDAC . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. of Patients . | % CR . | 95% CI (%) . | % RD . | 95% CI (%) . | No. of Patients . | % CR . | 95% CI (%) . | % RD . | 95% CI (%) . | |
| MDR1 (MRK16) | ||||||||||
| Bright | 43 | 49 | 34-64 | 35 | 21-49 | 21 | 48 | 26-69 | 38 | 17-59 |
| Moderate | 26 | 46 | 27-65 | 42 | 23-61 | 9 | 44 | 14-79 | 22 | 3-60 |
| Dim | 16 | 69 | 41-85 | 25 | 7-52 | 8 | 50 | 16-84 | 25 | 3-65 |
| Negative | 160 | 52 | 44-60 | 25 | 18-32 | 68 | 59 | 47-71 | 19 | 10-28 |